By Ben Hirschler
MUNICH, Aug 31 (Reuters) - AstraZeneca's cholesterol drug Crestor has failed in a second clinical trial for heart failure, suggesting such statin medicines don't improve survival in patients with the chronic condition.
Patients given Crestor proved just as likely to die early or be admitted to hospital with cardiovascular problems as those on standard therapy alone, researchers told the European Society of Cardiology annual meeting on Sunday.
In the latest so-called GISSI-HF study, involving 4,500 patients followed for an average of 3.9 years, 29 percent of people taking Crestor died from any cause against 28 percent of those given a placebo, or dummy, pill.
More
No comments:
Post a Comment